Protalix BioTherapeutics, Inc. Business Finance Contracts & Agreements

43 Contracts & Agreements
Browse by Subcategory
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Description of Capital Stock of Protalix BioTherapeutics, Inc.
Stock Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
2025
Amendment to At The Market Offering Agreement between Protalix BioTherapeutics, Inc. and H.C. Wainwright & Co., LLC (March 17, 2025)
Equity Distribution Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
2025
Description of Capital Stock of Protalix BioTherapeutics, Inc.
Stock Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
2024
At The Market Offering Agreement between Protalix BioTherapeutics, Inc. and H.C. Wainwright & Co., LLC (February 27, 2023)
Equity Distribution Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
NY
2023
Description of Capital Stock of Protalix BioTherapeutics, Inc.
Stock Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
2023
Amendment to At The Market Offering Agreement between Protalix BioTherapeutics, Inc. and H.C. Wainwright & Co., LLC (May 2, 2022)
Equity Distribution Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
2022
Third Supplemental Indenture to 7.50% Senior Secured Convertible Notes Due 2021—Protalix BioTherapeutics, Inc., Guarantors, The Bank of New York Mellon Trust Company, and...
Indenture Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
NY
2021
At The Market Offering Agreement between Protalix BioTherapeutics, Inc. and H.C. Wainwright & Co., LLC (July 2, 2021)
Equity Distribution Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
NY
2021
Binding Term Sheet for Amendment of Exclusive License and Supply Agreements between Chiesi Farmaceutici S.p.A. and Protalix Ltd.
Term Sheets
Protalix BioTherapeutics, Inc.
Biotechnology
NY
2021
ATM Equity Offering Sales Agreement between Protalix BioTherapeutics, Inc. and BofA Securities, Inc.
Equity Distribution Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
NY
2020
Description of Capital Stock of Protalix BioTherapeutics, Inc.
Stock Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
2020
Second Supplemental Indenture to 7.50% Senior Secured Convertible Notes Due 2021—Protalix BioTherapeutics, Inc., Guarantors, and The Bank of New York Mellon Trust Company, N.A.
Indenture Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
NY
2017
Note Purchase Agreement between Protalix BioTherapeutics, Inc. and Purchasers (July 24, 2017)
Note Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
NY
2017
Protalix BioTherapeutics, Inc. 4.50% Convertible Senior Notes Due 2022 (Global Note)
Note Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
2017
First Supplemental Indenture to 7.50% Senior Secured Convertible Notes Due 2021 – Protalix BioTherapeutics, Inc., The Bank of New York Mellon Trust Company, N.A., and Wilmington...
Indenture Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
NY
2017
Indenture for 4.50% Convertible Senior Notes due 2022 between Protalix BioTherapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A.
Indenture Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
NY
2017
Note Purchase Agreement between Protalix BioTherapeutics, Inc. and Purchasers (December 1, 2016)
Note Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
NY
2016
Protalix BioTherapeutics, Inc. 7.50% Senior Secured Convertible Notes Due 2021 Global Note
Note Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
NY
2016
Protalix BioTherapeutics, Inc. 7.50% Senior Secured Convertible Notes Due 2021 Global Note
Note Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
NY
2016
Indenture for 7.50% Senior Secured Convertible Notes Due 2021 by Protalix Biotherapeutics, Inc.
Indenture Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
NY
2016
Protalix BioTherapeutics, Inc. 4.50% Convertible Senior Notes Due 2018 (Global Note)
Note Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
2013
Indenture for 4.50% Convertible Senior Notes due 2018 between Protalix BioTherapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A.
Indenture Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
NY
2013
First Amendment to Stock Option Award Agreement between Protalix BioTherapeutics, Inc. and Steven Rubin
Stock Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
2007
First Amendment to Stock Option Award Agreement between Protalix BioTherapeutics, Inc. and Jane Hsiao, Ph.D.
Stock Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
2007
Exchange Agreement between Protalix BioTherapeutics, Inc. and Noteholders (August 12, 2021)
Exchange Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
NY
2021
Underwriting Agreement between Protalix BioTherapeutics, Inc. and BofA Securities, Inc. for Sale of Common Stock
Underwriting Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
NY
2021
Protalix BioTherapeutics, Inc. Employee Stock Option Agreement under 2006 Stock Incentive Plan
Warrant Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
2020
Protalix BioTherapeutics, Inc. Executive Officer Stock Option Agreement
Warrant Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
2020
Securities Purchase Agreement between Protalix BioTherapeutics, Inc. and Purchaser (March 2020)
Purchase Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
NY
2020
Warrant Agreement to Purchase Common Stock of Protalix BioTherapeutics, Inc. – March 2020
Warrant Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
NY
2020
Exchange Agreement between Protalix BioTherapeutics, Inc. and Noteholders (July 24, 2017)
Exchange Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
NY
2017
Security Agreement/Debenture between Protalix BioTherapeutics, Inc. and Altshuler Shaham Trusts Ltd. (December 7, 2016)
Security Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
NY
2016
Security Agreement among Protalix BioTherapeutics, Inc., Guarantors, and Wilmington Savings Fund Society, FSB (Collateral Agent)
Security Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
NY
2016
Exchange Agreement between Protalix BioTherapeutics, Inc. and Noteholders (December 1, 2016)
Exchange Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
NY
2016
Protalix BioTherapeutics, Inc. $60,000,000 4.50% Convertible Notes Due 2018 Purchase Agreement with Citigroup Global Markets Inc.
Purchase Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
NY
2013
Underwriting Agreement between Protalix BioTherapeutics, Inc. and Jefferies & Company, Inc. for Sale of Common Stock
Underwriting Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
NY
2012
Protalix BioTherapeutics, Inc. Underwriting Agreement for 4,000,000 Shares of Common Stock
Underwriting Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
NY
2011
Underwriting Agreement between Protalix BioTherapeutics, Inc. and UBS Securities LLC, dated October 24, 2007
Underwriting Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
NY
2007
First Amendment to Stock Option Award Agreement between Protalix BioTherapeutics, Inc. and Phillip Frost, M.D.
Modification Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
2007
Orthodontix, Inc. Stock Option Award Agreement with Steven Rubin
Warrant Agreements
Protalix BioTherapeutics, Inc.
Biotechnology
FL
2007